Dividend Growth Investing

dividends stocks investing

  • Home
  • About
  • Bookstore
  • Returns Calculator
  • Portfolio
  • Getting Started

Philip Morris gets Smoked

April 22, 2018 by Mike M Leave a Comment

Philip Morris recently reported earnings and shares have been in a freefall. The stock fell nearly 18% towards the end of the week. PM is now trading around $84/share down from $120 last summer. This was due to falling cigarette volumes and a perceived slowdown in demand for reduced risk products. On the bright side, the dividend has been pushed to 5%, sweeting the deal for income investors. The question remains, is Philip Morris International really in trouble? Is this stock oversold?

Unlike the past four years, in the current quarter, revenue was up 14% YOY to $6.89 billion. This figure still missed analyst estimates by $100 million. Another concern was how expenses increased as the company marketed its new products. This caused earnings to come in at $1.00/share, down $0.02 from last year. However, for the year, PM and most analysts expect to see over $5.00/share. There is certainly cause for concern, but the sky isn’t necessarily falling. Earnings have remained relatively steady and reduce risk products continue to become a greater share of total revenue.

The main reason earnings failed to meet expectations was because of a 20% increase in the cost of sales. Furthermore, marketing and research costs rose 26% to $1.83 billion. This comes as Philip Morris focuses on heated products and less on traditional combustible cigarettes. These expenses are unfortunate but necessary given the declining volume in cigarette shipments. If PM relied solely on combustible cigarettes the company would most likely be in a perpetual state of decline. However, the development and success of these reduce risk products is very compelling.

Reduced risk products, now account for $1.1 billion, or 16% of revenues. This number is expected to increase substantially in the future, despite a small slowdown in Japan. PM still has numerous geographic markets and age groups to penetrate. PM was highly successful in converting millennial consumers. They’re now tasked with converting older, more conservative smokers. New geographic markets PM is targeting are vast and even include the U.S. If the FDA approves, PM will be able to license iQOS technology through Altria (MO) and begin selling in the U.S. While there is cause for concern, I intend on holding on to PM. Despite some moderate risk there is still tremendous opportunity.

DISCLAIMER: I am not a licensed investment advisor or tax professional. I am not liable for any losses incurred by any parties. This blog should be viewed for entertainment and/or educational purposes only. Any transactions published are not recommendations to buy or sell any securities. Please consult with an investment professional before making investment decisions.

Filed Under: News & Current Events Tagged With: cigarettes, dividends, earnings, iQOS, revenue, risk, tobacco

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Dividend Investors:

Subscribe here for my latest content!

Connect with me on social media!

Featured Book:

Click the above image to see on Amazon.

Recent Posts

  • January 2021 (1)
  • December 2020 (1)
  • November 2020 (1)
  • October 2020 (1)
  • September 2020 (1)
  • July 2020 (1)
  • June 2020 (2)
  • May 2020 (1)
  • April 2020 (2)
  • March 2020 (1)
  • February 2020 (1)
  • January 2020 (1)
  • December 2019 (2)
  • November 2019 (2)
  • October 2019 (3)
  • September 2019 (5)
  • August 2019 (2)
  • July 2019 (1)
  • June 2019 (3)
  • May 2019 (3)
  • April 2019 (2)
  • March 2019 (1)
  • February 2019 (1)
  • January 2019 (2)
  • December 2018 (2)
  • November 2018 (2)
  • October 2018 (1)
  • September 2018 (2)
  • August 2018 (2)
  • July 2018 (2)
  • June 2018 (3)
  • May 2018 (3)
  • April 2018 (3)
  • March 2018 (3)
  • February 2018 (2)
  • January 2018 (2)
  • December 2017 (3)
  • November 2017 (2)
  • October 2017 (2)
  • September 2017 (3)
  • August 2017 (3)
  • July 2017 (4)
  • June 2017 (3)
  • May 2017 (3)
  • April 2017 (3)
  • March 2017 (3)
  • February 2017 (2)
  • January 2017 (3)
  • December 2016 (3)
  • November 2016 (2)
  • October 2016 (3)
  • September 2016 (2)
  • August 2016 (4)
  • July 2016 (4)
  • June 2016 (3)
  • May 2016 (3)
  • April 2016 (4)
  • March 2016 (5)
  • February 2016 (4)

Calendar

March 2021
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
« Jan    

Disclaimer

I am not a licensed investment advisor or tax professional. I am not liable for any losses incurred by any parties. This blog should be viewed for entertainment and/or educational purposes only. Any transactions published are not recommendations to buy or sell any securities. Please consult with an investment professional before making investment decisions.

Privacy Policy

This blog does not collect any personal information except that which is freely shared publicly. I will never sell personal information of any visitors for any purpose.

Disclosure

This blog may have third-party ads served up at any time. I do not make any claims to accuracy of these ads, and these ads do not necessarily represent this blog's views or opinions. I will note any Affiliate partner links I recommend and receive compensation for. We may also publish articles that are paid for by third-party advertisers, and these will be categorized as sponsored posts.

Copyright © 2021 · Author Pro Theme on Genesis Framework · WordPress · Log in

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT